|Videos|March 31, 2022
A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.
Advertisement
Episodes in this series
Advertisement
Related to this article
Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5